We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
-0.05%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$381M
AUM Growth
-$49.9M
(-12%)
Cap. Flow
-$22.9M
Cap. Flow
% of AUM
-6%
Top 10 Holdings %
Top 10 Hldgs %
22.14%
Holding
176
New
41
Increased
28
Reduced
15
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keros Therapeutics
KROS
|
+$4.48M |
| 2 |
Flux Power
FLUX
|
+$4.41M |
| 3 |
X4 Pharmaceuticals
XFOR
|
+$4.41M |
| 4 |
AFMD
Affimed
AFMD
|
+$4.38M |
| 5 |
Celldex Therapeutics
CLDX
|
+$4.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palisade Bio
PALI
|
+$7.43M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$7.11M |
| 3 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$6.25M |
| 4 |
EPIX
ESSA Pharma
EPIX
|
+$6.1M |
| 5 |
electroCore
ECOR
|
+$5.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.97% |
| 2 | Financials | 5.73% |
| 3 | Technology | 2.04% |
| 4 | Industrials | 1.47% |
| 5 | Communication Services | 1.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Haemonetics
HAE
$3.88B
| $5.22M | 1.37% |
74,000
+21,000
| +40% | +$1.33M |
|
27
Myriad Genetics
MYGN
$295M
| $5.1M | 1.34% |
158,000
-13,242
| -8% | -$440K |
|
28
Natera
NTRA
$38B
| $5.07M | 1.33% |
45,500
+12,270
| +37% | +$1.41M |
|
|
LITS
29
Lite Strategy Inc
LITS
$32.9M
| $5.04M | 1.32% |
91,403
| – | – |
|
|
MBTC
30
DELISTED
Nocturne Acquisition Corporation Ordinary Shares
MBTC
| $4.99M | 1.31% |
500,000
| – | – |
|
|
31
Keros Therapeutics
KROS
$200M
| $4.99M | 1.31% |
+126,000
| New | +$4.48M |
|
32
Spyre Therapeutics
SYRE
$9.16B
| $4.85M | 1.27% |
24,388
| – | – |
|
33
Castle Biosciences
CSTL
$912M
| $4.82M | 1.26% |
72,500
+3,500
| +5% | +$246K |
|
34
Varex Imaging
VREX
$518M
| $4.46M | 1.17% |
158,000
+16,681
| +12% | +$463K |
|
|
AVDL
35
DELISTED
Avadel Pharmaceuticals
AVDL
| $4.32M | 1.13% |
440,589
| – | – |
|
|
36
X4 Pharmaceuticals
XFOR
$390M
| $4.26M | 1.12% |
+26,820
| New | +$4.41M |
|
|
AFMD
37
DELISTED
Affimed
AFMD
| $4.11M | 1.08% |
+66,500
| New | +$4.38M |
|
|
38
Crinetics Pharmaceuticals
CRNX
$8.92B
| $4.06M | 1.07% |
193,000
-340,033
| -64% | -$7.11M |
|
39
Illumina
ILMN
$28.8B
| $4.06M | 1.06% |
10,280
+2,056
| +25% | +$946K |
|
|
EUCR
40
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
| $3.91M | 1.03% |
400,000
| – | – |
|
41
EyePoint Inc
EYPT
$1.08B
| $3.86M | 1.01% |
370,551
| – | – |
|
|
BCYC
42
Bicycle Therapeutics
BCYC
$277M
| $3.83M | 1% |
+92,000
| New | +$3.22M |
|
43
Arcturus Therapeutics
ARCT
$171M
| $3.82M | 1% |
+80,000
| New | +$3.58M |
|
44
BridgeBio Pharma
BBIO
$16.1B
| $3.7M | 0.97% |
+79,000
| New | +$4.23M |
|
|
RCOR
45
DELISTED
Renovacor, Inc.
RCOR
| $3.52M | 0.92% |
388,845
-365,029
| -48% | -$3.56M |
|
|
ICAD
46
DELISTED
iCAD Inc
ICAD
| $3.44M | 0.9% |
+320,000
| New | +$4.16M |
|
|
PROF
47
Profound Medical
PROF
$295M
| $3.44M | 0.9% |
235,000
+24,720
| +12% | +$377K |
|
48
Travere Therapeutics
TVTX
$6.08B
| $3.42M | 0.9% |
141,000
-29,484
| -17% | -$542K |
|
|
MORF
49
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $3.4M | 0.89% |
60,000
+19,459
| +48% | +$1.18M |
|
50
Xenon Pharmaceuticals
XENE
$6.21B
| $3.3M | 0.87% |
216,000
+61,000
| +39% | +$1.06M |
|
Similar funds
TA
SIM
LSA
VEPM
VI
BCM
VAM
SCM
Altium Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Altium Capital Management held 176 positions worth $381M, down 12% from $431M the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Altium Capital Management withdrew a net $22.9M in Q3 2021, closing 51 positions and reducing 15 holdings. Its most notable exit was Palisade Bio, an estimated $7.43M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 85% a quarter earlier, followed by Financials and Technology.
Against the trend, Altium Capital Management opened a new position in Keros Therapeutics worth $4.99M.
- Altium Capital Management's largest Q3 2021 buy was Keros Therapeutics: 126,000 shares worth $4.99M.
- Altium Capital Management added most to Celldex Therapeutics in Q3 2021, an estimated $4.31M increase.
- Altium Capital Management's biggest Q3 2021 reduction was Crinetics Pharmaceuticals, cutting an estimated $7.11M.
- Altium Capital Management fully exited Palisade Bio in Q3 2021, selling an estimated $7.43M.
- Altium Capital Management's ten largest holdings make up 22% of its $381M portfolio in Q3 2021.
- Altium Capital Management opened 41 new positions and closed 51 in Q3 2021.
- Altium Capital Management's portfolio value fell 12% quarter-over-quarter to $381M.
Based on Altium Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.